Form 4: Director Kolli Reports Zimmer Biomet Holdings Stock Transactions

Director Sreelakshmi Kolli of Zimmer Biomet Holdings, Inc. has reported transactions related to phantom stock units, indicating changes in beneficial ownership.

Summary

• Director Sreelakshmi Kolli reported transactions concerning phantom stock units under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
• The phantom stock units have a conversion or exercise price of 1-for-1.
• These units are to be settled in shares of Company common stock within sixty days after the cessation of Kolli's service as a Director.
• The earliest transaction date reported is June 30, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents routine transactions under a director's compensation plan rather than a significant strategic event or a change in investment conviction.

Positives

• Director Kolli's transactions are part of a standard deferred compensation plan for non-employee directors, suggesting ongoing engagement and alignment with the company's long-term performance.
• The settlement of phantom stock units in company common stock ensures that the director's interest remains tied to shareholder value.

Negatives

• The filing does not provide specific details on the number of units disposed of or acquired, only the total amount beneficially owned following the reported transactions (6,842.604 shares).

Risks

• The settlement of phantom stock units is contingent upon the cessation of service as a Director, which could be influenced by various factors not detailed in the filing.
• The value of the phantom stock units is tied to the company's common stock price, exposing the director to market volatility.

Future Outlook

The phantom stock units are to be settled in shares of Company common stock within sixty days after the reporting person's cessation of service as a Director. The specific number of units subject to this settlement is not detailed, but the total beneficial ownership following reported transactions is 6,842.604 shares.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. This particular filing relates to a director's participation in a deferred compensation plan, a common practice in the medical device industry to attract and retain experienced board members.

Related Party Transactions

• Transactions related to phantom stock units under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.

Stakeholder Impact

• Shareholders: The filing provides transparency on director compensation and potential future share issuance, impacting diluted share count.

Next Steps

• Settlement of phantom stock units in company common stock within sixty days after the reporting person's cessation of service as a Director.

Key Dates

Keywords

Zimmer Biomet Holdings, ZBH, Form 4, SEC Filing, Director, Beneficial Ownership, Phantom Stock Units, Deferred Compensation Plan, Insider Trading, Stock Transactions